BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang DY, Hou YQ, Luo LJ, Ao L. Altered expression of miR-92a correlates with Th17 cell frequency in patients with primary biliary cirrhosis. Int J Mol Med 2016;38:131-8. [PMID: 27246196 DOI: 10.3892/ijmm.2016.2610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Jiao Z, Chen M, Shen B, Shuai Z. Roles of Non-Coding RNAs in Primary Biliary Cholangitis. Front Mol Biosci 2022;9:915993. [DOI: 10.3389/fmolb.2022.915993] [Reference Citation Analysis]
2 Gerussi A, Paraboschi EM, Cappadona C, Caime C, Binatti E, Cristoferi L, Asselta R, Invernizzi P. The Role of Epigenetics in Primary Biliary Cholangitis. Int J Mol Sci 2022;23:4873. [PMID: 35563266 DOI: 10.3390/ijms23094873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Tadokoro T, Morishita A, Masaki T. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. Int J Mol Sci 2021;22:8139. [PMID: 34360904 DOI: 10.3390/ijms22158139] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
4 Huang C, Xing X, Xiang X, Fan X, Men R, Ye T, Yang L. MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Biomed Pharmacother 2020;130:110558. [PMID: 32781357 DOI: 10.1016/j.biopha.2020.110558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xuan J, Huang A, Hu D, Geng J, Tian Y, Cheng Z, Qiu Y. Huagan tongluo Fang improves liver fibrosis via down-regulating miR-184 and up-regulating FOXO1 to inhibit Th17 cell differentiation. Exp Mol Pathol 2020;115:104447. [PMID: 32380055 DOI: 10.1016/j.yexmp.2020.104447] [Reference Citation Analysis]
6 Zhang L, Wu H, Zhao M, Chang C, Lu Q. Clinical significance of miRNAs in autoimmunity. J Autoimmun 2020;109:102438. [PMID: 32184036 DOI: 10.1016/j.jaut.2020.102438] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
7 Gado MM, Mousa NO, Badawy MA, El Taweel MA, Osman A. Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia. Asian Pac J Cancer Prev 2019;20:3625-33. [PMID: 31870103 DOI: 10.31557/APJCP.2019.20.12.3625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, Dalekos GN, Renaudineau Y. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. Epigenomes 2019;3:15. [PMID: 34968227 DOI: 10.3390/epigenomes3030015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Sun Q, Wang Q, Feng N, Meng Y, Li B, Luo D, Shang X, Lv J, Monsaf AM, Wang C, Ma X. The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis. Ann Transl Med 2019;7:389. [PMID: 31555703 DOI: 10.21037/atm.2019.07.100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Chon HS, Sehovic M, Marchion D, Walko C, Xiong Y, Extermann M. Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging. J Cancer 2019;10:2604-18. [PMID: 31258768 DOI: 10.7150/jca.29611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Ma W, Chen D. Immunological abnormalities in patients with primary biliary cholangitis. Clinical Science 2019;133:741-60. [DOI: 10.1042/cs20181123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
12 Liu Q, Li Y, Ma X, Tang R. Epigenetics of autoimmune liver diseases: current progress and future directions. Journal of Bio-X Research 2019;2:46-55. [DOI: 10.1097/jbr.0000000000000030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Rodrigues PM, Perugorria MJ, Santos-laso A, Bujanda L, Beuers U, Banales JM. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure? Journal of Hepatology 2018;69:1371-83. [DOI: 10.1016/j.jhep.2018.08.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
14 Song Y, Yang H, Jiang K, Wang B, Lin R. miR-181a regulates Th17 cells distribution via up-regulated BCL-2 in primary biliary cholangitis. International Immunopharmacology 2018;64:386-93. [DOI: 10.1016/j.intimp.2018.09.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Jadideslam G, Ansarin K, Sakhinia E, Alipour S, Pouremamali F, Khabbazi A. The MicroRNA-326: Autoimmune diseases, diagnostic biomarker, and therapeutic target. J Cell Physiol 2018;233:9209-22. [PMID: 30078204 DOI: 10.1002/jcp.26949] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
16 Tanaka A, Leung PS, Gershwin ME. The Genetics and Epigenetics of Primary Biliary Cholangitis. Clinics in Liver Disease 2018;22:443-55. [DOI: 10.1016/j.cld.2018.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
17 Kouroumalis E, Samonakis D, Voumvouraki A. Biomarkers for primary biliary cholangitis: current perspectives. Hepat Med 2018;10:43-53. [PMID: 29950909 DOI: 10.2147/HMER.S135337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tanaka A, Leung PS, Gershwin ME. Evolution of our understanding of PBC. Best Practice & Research Clinical Gastroenterology 2018;34-35:3-9. [DOI: 10.1016/j.bpg.2018.05.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
19 Gulamhusein AF, Hirschfield GM. Pathophysiology of primary biliary cholangitis. Best Practice & Research Clinical Gastroenterology 2018;34-35:17-25. [DOI: 10.1016/j.bpg.2018.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
20 Arsenijevic A, Harrell CR, Fellabaum C, Volarevic V. Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis. Anal Cell Pathol (Amst) 2017;2017:7492836. [PMID: 29410945 DOI: 10.1155/2017/7492836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kennedy I, Francis H, Meng F, Glaser S, Alpini G. Diagnostic and therapeutic potentials of microRNAs in cholangiopathies. Liver Res 2017;1:34-41. [PMID: 29085701 DOI: 10.1016/j.livres.2017.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]